BioSapien kimyoterapiya yetkazib berish texnologiyasini rivojlantirish maqsadida pre-Seriya A investitsiyasini $7 million dollarga kengaytirdi
Ushbu investitsiya Golden Gate Ventures’ MENA Fund tomonidan qo‘llab-quvvatlandi va bu fondning mintaqadagi ilk sarmoyasidir.
👉 Batafsil
—
BioSapien has expanded its pre-Series A funding round to $7 million to advance its chemotherapy delivery technology!
This investment, led by Golden Gate Ventures’ MENA Fund, marks the fund’s first investment in the region.
👉 For more information
Instagram | LinkedIn | X (Twitter) | Facebook | YouTube
Ushbu investitsiya Golden Gate Ventures’ MENA Fund tomonidan qo‘llab-quvvatlandi va bu fondning mintaqadagi ilk sarmoyasidir.
MediChip texnologiyasi minimal invaziv usulda kimyoterapiyani bevosita o‘simtaga yetkazib berib, an’anaviy usullarga qaraganda kamroq nojo‘ya ta’sirlarni keltirib chiqaradi. BAAda klinik sinovlar 2025-yil 2-choragida boshlanishi rejalashtirilgan.
👉 Batafsil
—
BioSapien has expanded its pre-Series A funding round to $7 million to advance its chemotherapy delivery technology!
This investment, led by Golden Gate Ventures’ MENA Fund, marks the fund’s first investment in the region.
MediChip
, a minimally invasive platform, delivers chemotherapy directly to tumors, significantly reducing side effects compared to traditional methods.
Clinical trials in the UAE are set to begin in Q2 2025!
👉 For more information
Instagram | LinkedIn | X (Twitter) | Facebook | YouTube